We evaluated the effects of treatment in diverse TME subtypes that are representative of human cancers undergoing trials with MRgFUS ablation: 1) a pancreatic tumor model with a dense stroma and sparse tumor cell distribution (based on the KPC model), and 2) an Her2+ epithelial breast tumor model (based on the PyMT model) with a dense tumor cell distribution and larger number of immune cells. The gene discussed is ERBB2; the disease is neoplasm.